Market Research Logo

Proteome Sciences Plc - Product Pipeline Review - 2015

Proteome Sciences Plc - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Proteome Sciences Plc - Product Pipeline Review - 2015’, provides an overview of the Proteome Sciences Plc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Proteome Sciences Plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Proteome Sciences Plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Proteome Sciences Plc’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Proteome Sciences Plc’s pipeline products
Reasons to buy
  • Evaluate Proteome Sciences Plc’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Proteome Sciences Plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Proteome Sciences Plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Proteome Sciences Plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Proteome Sciences Plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Proteome Sciences Plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Proteome Sciences Plc Snapshot
Proteome Sciences Plc Overview
Key Information
Key Facts
Proteome Sciences Plc - Research and Development Overview
Key Therapeutic Areas
Proteome Sciences Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Proteome Sciences Plc - Pipeline Products Glance
Proteome Sciences Plc - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Proteome Sciences Plc - Drug Profiles
PS-110
Product Description
Mechanism of Action
R&D Progress
PS-278
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit CK1D for Alzheimer's Disease
Product Description
Mechanism of Action
R&D Progress
Proteome Sciences Plc - Pipeline Analysis
Proteome Sciences Plc - Pipeline Products by Target
Proteome Sciences Plc - Pipeline Products by Route of Administration
Proteome Sciences Plc - Pipeline Products by Molecule Type
Proteome Sciences Plc - Pipeline Products by Mechanism of Action
Proteome Sciences Plc - Recent Pipeline Updates
Proteome Sciences Plc - Company Statement
Proteome Sciences Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Proteome Sciences Plc, Key Information
Proteome Sciences Plc, Key Facts
Proteome Sciences Plc - Pipeline by Indication, 2015
Proteome Sciences Plc - Pipeline by Stage of Development, 2015
Proteome Sciences Plc - Monotherapy Products in Pipeline, 2015
Proteome Sciences Plc - Preclinical, 2015
Proteome Sciences Plc - Pipeline by Target, 2015
Proteome Sciences Plc - Pipeline by Route of Administration, 2015
Proteome Sciences Plc - Pipeline by Molecule Type, 2015
Proteome Sciences Plc - Pipeline Products by Mechanism of Action, 2015
Proteome Sciences Plc - Recent Pipeline Updates, 2015
Proteome Sciences Plc, Subsidiaries

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report